IMARA Inc (IMRA) Quote

Why? Thought it is negative.

Looking. Tight might pop but Friday

Just as long as I'm out before it gets delisted is all that matters! :)

IMRA: And, we are being "INVESTIGATED", to boot!!! THAT alone should send this puppy to the MOON!!!

https://seekingalpha.com/news/3891238-cancer-drug-developer-enliven-therapeutics-and-imara-to-merge-in-all-stock-deal

https://www.benzinga.com/pressreleases/22/10/29266700/shareholder-notice-brodsky-smith-announces-an-investigation-of-imara-inc-imra

Imra merger with who

Who needs an active board anyway when we have this!
Enliven Therapeutics and Imara Announce Merger Agreement
October 13 2022 - 04:35PM
GlobeNewswire Inc.
Alert
Print
Share On Facebook

Enliven Therapeutics, Inc. (Enliven), a clinical-stage precision oncology company focused on the discovery and development of next-generation small molecule kinase inhibitors, and Imara Inc. (Nasdaq: IMRA) (Imara) today announced that they have entered into a definitive merger agreement to combine the companies in an all-stock transaction. The combined company will focus on advancing Enliven’s pipeline of precision oncology product candidates. Enliven is advancing two parallel lead product candidates: ELVN-001, a highly selective small molecule BCR-ABL inhibitor designed to address the challenges that limit the efficacy, tolerability and convenience of currently available adenosine triphosphate (ATP)-competitive tyrosine kinase inhibitors (TKIs) in the treatment of chronic myeloid leukemia (CML), and ELVN-002, a potent, selective and irreversible HER2 and pan-HER2 mutant kinase inhibitor for the treatment of HER2 mutant lung cancer and other HER2-driven tumor types. Upon completion of the merger, which is subject to approval by Imara’s and Enliven’s stockholders, the combined company is expected to operate under the name Enliven Therapeutics, Inc. and trade on the Nasdaq Global Select Market under the ticker symbol ELVN.
In support of the merger, Enliven also intends to raise approximately $165 million in a concurrent private financing co-led by new investors Fairmount and Venrock Healthcare Capital Partners, with participation from additional new investors, which include Fidelity Management & Research Company, RA Capital Management, Frazier Life Sciences and Commodore Capital. All of Enliven’s existing investors will participate in the financing, including OrbiMed, 5AM Ventures, Surveyor Capital (a Citadel company), Cormorant Asset Management, Roche Venture Fund, Sheatree Capital, Boxer Capital, Logos Capital and Janus Henderson Investors. The financing was oversubscribed and new investor allocations account for over 60% of the total size of the financing, which is expected to close immediately prior to the completion of the merger.

With the cash expected from both companies at closing and the proceeds of the planned concurrent financing, the combined company is currently expected to have approximately $300 million of cash and cash equivalents at closing, after transaction expenses. The cash resources are expected to be used to advance Enliven’s pipeline through multiple clinical milestones and provide runway into early 2026. The merger and financing are expected to close in the first quarter of 2023, subject to stockholder approval of both companies, the effectiveness of a registration statement to be filed with the U.S. Securities and Exchange Commission (SEC) to register the shares of Imara common stock to be issued in connection with the merger, and the satisfaction of customary closing conditions.

“We are excited to announce this merger with Imara, which comes at a pivotal moment for Enliven. We recently initiated our Phase 1 clinical trial for ELVN-001, which is being evaluated in adults with CML, and expect to file our IND for ELVN-002 by the end of the year. We expect this transaction to provide Enliven with capital to fund us through multiple key milestones and allow us to explore the potential of our pipeline. We look forward to helping people with cancer to not only live longer, but live better,” said Sam Kintz, MBA, Enliven’s Co-founder and Chief Executive Officer.

“Following an extensive and thoughtful review of several strategic alternatives, it became clear that the proposed merger with Enliven was a compelling option for our stockholders,” said Rahul Ballal, Ph.D., President and Chief Executive Officer of Imara. “Enliven has a differentiated pipeline, an experienced team and we expect the combined company to be well financed by top-tier investors to execute on its clinical mission. We look forward to the company’s continued progress in the clinic.”

About Enliven’s Precision Oncology Portfolio

Enliven is a clinical-stage precision oncology company focused on the discovery and development of potentially best-in-class or first-in-class precision oncology therapies. Enliven’s programs are designed to address issues such as tolerability, combinability, resistance and disease escape through brain metastases. Enliven is advancing two parallel lead product candidates:

ELVN-001: Enliven’s most advanced candidate, ELVN-001, is a potent, highly selective, small molecule kinase inhibitor designed to specifically target the BCR-ABL gene fusion, the oncogenic driver for patients with CML. Although the approval of BCR-ABL TKIs has improved the life expectancy of patients with CM

On September 6, 2022, IMARA Inc., a Delaware corporation (the “Company”), entered into an Asset Purchase Agreement (the “Asset Purchase Agreement”) with Cardurion Pharmaceuticals, Inc. (“Cardurion”), providing for the sale of tovinontrine (IMR-687) and all other assets of the Company related to its PDE9 program (the “Asset Sale”). In addition to $250,000 previously paid by Cardurion to the Company upon execution of a non-binding term sheet, the aggregate purchase price consists of an upfront cash payment of $34,750,000 upon closing of the transaction and a $10,000,000 potential future payment that may become payable if Cardurion achieves a proof of concept milestone or other specified clinical milestones and a $50,000,000 potential future payment that may become payable if Cardurion achieves specified regulatory and/or commercial milestone events, in each case as described in the Asset Purchase Agreement and subject to the terms of the Asset Purchase Agreement.

WOW!! What an ACTIVE Board THIS one was yesterday!! I simply could NOT keep pace with the HUNDREDS of posts in there!!!

YOU SEE WHAT ISEE

AUG 5
https://ih.advfn.com/stock-market/NASDAQ/imara-IMRA/stock-news/88768037/imara-imra-receives-a-hold-from-h-c-wainwright

SEP 7
https://ih.advfn.com/stock-market/NASDAQ/imara-IMRA/stock-news/89007691/imara-imra-gets-a-hold-from-h-c-wainwright

OF COURSE i BET ON THE WRONG HORSE

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=169889329

IMRA: WHAT??? Is it gonna break that $2.00 barrier???

IMRA: Hey, fluck this deadbeat Board!! I'm goin' to VEGAS, for my gambling addiction!! At least THERE, I might meet a, 'Hot-Blonde-CHICK!! (Like below!!)


(HOT BLONDE CHICK)

IMRA: Are you ALIVE, Imara Company?? Or DEAD?? (See TESTS, below.)


The classic, "Alive-Or-Dead-Vertical-Standing", test.


Dead Cat "CPR" routine!!

IMRA: If this can't bust $2.00 today, then it's a classic (NASDAQ) P.O.S.!! (Truth be told.)

IMRA: Well, this sure ain't a very ACTIVE iHub Board!! WAKE-UP, Peeps, & smell those lunchtime LATTES!!! (With 3-scoops of ice cream, to boot!!)

IMRA: This is IMRA Central Command to High Seas Fleet!! OPEN FIRE!!

IMRA: News behind that Drug purchase now getting out; could get a good run here to Close today. (Maybe???)

an upfront cash payment of $34,750,000 https://ih.advfn.com/stock-market/NASDAQ/imara-IMRA/stock-news/89005774/additional-proxy-soliciting-materials-definitive-d

Does this mean the stock will keep bleeding out? None of this sounds like good news. Lol.

IMRA terminates all clinical programs—lays_off_all_but_6_employees:

https://www.sec.gov/ix?doc=/Archives/edgar/data/0001672619/000156459022014494/imra-8k_20220405.htm On April 12, 2022, the Board of Directors (“Board”) of IMARA Inc. (the “Company”) approved a reduction of the Company’s workforce (the “Workforce Reduction”) by approximately 83% across all areas of the Company, to a total of six remaining full-time employees.

The Workforce Reduction follows the Company’s decision, further described below, to discontinue development of tovinontrine (IMR-687) in sickle cell disease, beta-thalassemia and heart failure with preserved ejection fraction, as well to discontinue its development plans with respect to IMR-261.

The Workforce Reduction is expected to be substantially completed by the end of the second quarter of 2022. The Workforce Reduction is designed to substantially reduce the Company’s operating expenses while the Company undertakes a comprehensive assessment of its strategic options to maximize shareholder value.

well we all know what happened now...$IMRA

$IMRA
$IMRA Just added to the Post Masters Telegram Room watchlist..chart looks like move just starting..
5000 members strong..we deliver!https://t.co/qZaQQOjnVVhttps://t.co/1HSlQfNws7 pic.twitter.com/F8g1Jo4C4E— Tommy Boy Trader (@QuabbinR) February 20, 2022

$4.23 nice spike

no followers. I think today's dip is a buying opportunity.

$6

$IMRA

Blasting off now let’s go

Swinging this in at 13.9 no brainer here

IMRA back to IPO prices...WOW!!! well hopefully this will pan out...

Crazy cheap shares in IMRA today.....I'm IN

Not much of a recovery for IMRA...

Panic selling for IMRA based on published results...